Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals announced positive five-year data for AMVUTTRA® (vutrisiran) in treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The findings, presented at the AHA Scientific Sessions 2026, highlight sustained benefits and robust TTR silencing from the HELIOS-B Phase 3 trial extension. This adds to the growing evidence supporting the drug's efficacy.

Market Sentiment Analysis

POSITIVE FACTORS

  • New data shows sustained benefit of AMVUTTRA® in ATTR-CM.
  • HELIOS-B Phase 3 extension demonstrates strong TTR silencing.
  • Findings presented at the AHA Scientific Sessions 2026.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+13%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Lead asset
ALN-4324
Phase 2 · Type 2 Diabetes Mellitus (T2DM)

Full Press Release Details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension (OLE) period, show that patients with transthyretin amyloidosis with cardiomyop

Frequently Asked Questions

What is AMVUTTRA® used for?

AMVUTTRA® is used to treat transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

What were the findings from the HELIOS-B trial?

The HELIOS-B trial showed sustained benefits of AMVUTTRA® over five years.

Where were the new data presented?

The new data were presented at the American Heart Association Scientific Sessions 2026.

What is the significance of TTR silencing?

TTR silencing is crucial for reducing the effects of transthyretin amyloidosis.

ShareAdd on Google
Tags: ALNY Alnylam AMVUTTRA ATTR-CM HELIOS-B RNAi therapeutics
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$3587M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 2
Type 2 Diabetes Mellitus (T2DM) →

Catalyst track record

+13%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →